HOYA CORPORATION PENTAX TOKYO OFFICE

What the Data Shows About HOYA CORPORATION PENTAX TOKYO OFFICE

HOYA CORPORATION PENTAX TOKYO OFFICE is associated with 47,155 adverse-event reports in the FDA Manufacturer and User Facility Device Experience (MAUDE) database , spanning reports dated from 2014 through 2026. Of the total, 30 are coded as death reports and 628 as injury reports, with the remainder classified as malfunctions or other event types. These counts reflect reports submitted to the FDA by manufacturers, healthcare facilities, and patients — they are raw signal, not adjudicated safety findings, and higher-volume manufacturers or older product portfolios naturally generate larger raw counts.

The reports span 20 distinct device types attributed to this manufacturer in MAUDE, which means any safety read for HOYA CORPORATION PENTAX TOKYO OFFICE should be reviewed at the device-family level rather than company-wide. Across those devices, 4 distinct event types appear in the record, led by Malfunction at 46,463 reports (98.5% of total). Patient-outcome categorizations are reported across 13 distinct outcomes, giving a shaped distribution rather than a single headline figure.

Year-over-year reporting volume is tracked across 13 years of MAUDE data, with the peak single-year volume reaching 12,912 reports — trend shape can reflect shifts in device sales, FDA reporting requirements, or post-market recall activity as much as intrinsic device performance. The MAUDE system is one input among many in FDA post-market surveillance and does not draw safety conclusions from individual submissions. All figures reflect the openFDA snapshot refreshed on 2026-05-15, and nothing on this page is medical or regulatory advice — consult a qualified clinician or the FDA for current safety communications.